Scancell (LON:SCLP) Shares Down 3.1% - Should You Sell?

Key Points

• Shares down 3.1%: Scancell fell 3.1% on Friday to GBX 12.50 (intraday low GBX 11.63) on light volume of ~444,921 shares, about 74% below its average daily volume.
• Company is unprofitable: Scancell reported GBX (0.55) EPS for the quarter, has a negative net margin (~116.98%) and negative P/E, with analysts forecasting roughly -2.54 EPS for the year and a market cap of ~£125.6m.
• Clinical‑stage immunotherapy focus: The firm develops Immunobody® and Moditope® therapies; lead candidate iSCIB1+ has shown monotherapy activity in adjuvant melanoma and added benefit when combined with checkpoint inhibitors in the Phase 2 SCOPE trial.

Scancell Holdings plc (LON:SCLP - Get Free Report) shares dropped 3.1% on Friday . The stock traded as low as GBX 11.63 and last traded at GBX 12.50. Approximately 444,921 shares changed hands during mid-day trading, a decline of 74% from the average daily volume of 1,685,915 shares. The stock had previously closed at GBX 12.90.

Scancell Stock Down 6.2%

The company has a debt-to-equity ratio of -193.29, a quick ratio of 13.01 and a current ratio of 0.56. The company's fifty day moving average price is GBX 12.87 and its 200-day moving average price is GBX 10.84. The stock has a market cap of £125.57 million, a P/E ratio of -22.00 and a beta of 0.33.

Scancell (LON:SCLP - Get Free Report) last issued its quarterly earnings results on Thursday, January 29th. The company reported GBX (0.55) EPS for the quarter. Scancell had a negative net margin of 116.98% and a positive return on equity of 90.29%. Equities analysts forecast that Scancell Holdings plc will post -2.5361112 EPS for the current year.

Scancell Company Profile

Scancell LSE: SCLP is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.